• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

造血干细胞移植后慢性肾脏病的发病率及危险因素

Incidence and risk factors for chronic kidney disease after hematopoietic stem cell transplantation.

作者信息

Tanase Alina, Andronesi Andreea, Sorohan Bogdan, Vasile Andreea, Lipan Lavinia, Varady Zsofia, Stefan Laura, Craciun Oana, Ranete Adela, Obrisca Bogdan, Cioata Rebeca, Ismail Gener

机构信息

Bone Marrow Transplant Department, Fundeni Clinical Institute, Bucharest, Romania.

Nephrology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

出版信息

Ren Fail. 2025 Dec;47(1):2535517. doi: 10.1080/0886022X.2025.2535517. Epub 2025 Aug 4.

DOI:10.1080/0886022X.2025.2535517
PMID:40755282
Abstract

BACKGROUND

Chronic kidney disease (CKD) in hematopoietic stem cell transplantation (HSCT) is becoming more common. Only few studies were published during the past 10 years. Identification of risk factors is of outmost importance.

OBJECTIVES

We assessed prospectively a cohort of 197 patients who underwent allogeneic HSCT, aiming to evaluate the incidence and risk factors associated with CKD. We registered the persistence of the low GFR. Cox proportional hazard analysis has been used to identify the risk factors.

MAIN RESULTS

The mean age was 38.7 years (52.8% female). Acute kidney injury was present in 80% patients within 3 months and CKD incidence was 11.7% with a median onset of 6 months. By univariate Cox regression analysis, age (per 1 year) was the only variable associated with CKD (HR= 1.06, 95%, CI= 1.02-1.10,  = 0.001) and baseline creatinine (per 1 mg/dl) presented a trend of association (HR= 4.62, 95%, CI= 0.75-28.42,  = 0.09). Multivariate Cox regression analysis showed that age (per 1 year; HR= 1.08, 95%, CI = 1.02-1.14,  = 0.003) and hematologic disease length (per 1 month; HR = 1.01, 95%, CI= 1.001-1.02,  = 0.02) were positive predictors for CKD, whereas acute lymphoblastic leukemia (HR= 0.37, 95%, CI= 0.20-0.61,  = 0.02) was a negative predictor factor, being associated with a 63% reduction risk for developing CKD.

CONCLUSIONS

As the prognostic of hematopoietic stem cell transplantation survivors is improving, CKD emerges as an important comorbidity, with hematologic disease length and baseline eGFR being independent risk factors for renal dysfunction.

摘要

背景

造血干细胞移植(HSCT)中的慢性肾脏病(CKD)正变得越来越常见。在过去10年中仅有少数研究发表。识别危险因素至关重要。

目的

我们前瞻性评估了197例接受异基因HSCT的患者队列,旨在评估CKD的发生率及相关危险因素。我们记录了低肾小球滤过率(GFR)的持续情况。采用Cox比例风险分析来识别危险因素。

主要结果

平均年龄为38.7岁(52.8%为女性)。80%的患者在3个月内出现急性肾损伤,CKD发生率为11.7%,中位发病时间为6个月。单因素Cox回归分析显示,年龄(每增加1岁)是与CKD相关的唯一变量(风险比[HR]=1.06,95%置信区间[CI]=1.02 - 1.10,P = 0.001),且基线肌酐(每增加1mg/dl)呈现出关联趋势(HR = 4.62,95% CI = 0.75 - 28.42,P = 0.09)。多因素Cox回归分析表明,年龄(每增加1岁;HR = 1.08,95% CI = 1.02 - 1.14,P = 0.003)和血液系统疾病病程(每增加1个月;HR = 1.01,95% CI = 1.001 - 1.02,P = 0.02)是CKD的阳性预测因素,而急性淋巴细胞白血病(HR = 0.37,95% CI = 0.20 - 0.61,P = 0.02)是阴性预测因素,与发生CKD的风险降低63%相关。

结论

随着造血干细胞移植幸存者的预后不断改善,CKD成为一种重要的合并症,血液系统疾病病程和基线估算肾小球滤过率(eGFR)是肾功能不全的独立危险因素。

相似文献

1
Incidence and risk factors for chronic kidney disease after hematopoietic stem cell transplantation.造血干细胞移植后慢性肾脏病的发病率及危险因素
Ren Fail. 2025 Dec;47(1):2535517. doi: 10.1080/0886022X.2025.2535517. Epub 2025 Aug 4.
2
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.成人血液系统恶性肿瘤的骨髓与外周血异基因造血干细胞移植
Cochrane Database Syst Rev. 2014 Apr 20;2014(4):CD010189. doi: 10.1002/14651858.CD010189.pub2.
3
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
4
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.多克隆抗胸腺细胞球蛋白用于预防成人异基因干细胞或骨髓移植后的移植物抗宿主病。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD009159. doi: 10.1002/14651858.CD009159.pub2.
5
Arterial Stiffness and Subsequent Incidence of CKD and Kidney Function Decline in a Large Longitudinal Community Cohort: The Atherosclerosis in Communities (ARIC) Study.大型纵向社区队列中动脉僵硬度与慢性肾脏病的后续发病率及肾功能下降:社区动脉粥样硬化风险(ARIC)研究
Am J Kidney Dis. 2025 Jul;86(1):32-42. doi: 10.1053/j.ajkd.2024.11.011. Epub 2025 Jan 23.
6
Association of Kidney Cysts With Progressive CKD After Radical Nephrectomy.肾囊肿与根治性肾切除术后进行性 CKD 的关系。
Am J Kidney Dis. 2024 Jul;84(1):62-72.e1. doi: 10.1053/j.ajkd.2023.11.016. Epub 2024 Jan 26.
7
Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation.性别作为肾移植后同种异体移植及患者相关预后的预测因素。
Cochrane Database Syst Rev. 2024 Dec 19;12(12):CD014966. doi: 10.1002/14651858.CD014966.pub2.
8
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.成人血液系统恶性肿瘤的骨髓与外周血异基因造血干细胞移植。
Cochrane Database Syst Rev. 2024 Nov 7;11(11):CD010189. doi: 10.1002/14651858.CD010189.pub3.
9
Antioxidants for chronic kidney disease.用于慢性肾病的抗氧化剂。
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD008176. doi: 10.1002/14651858.CD008176.pub2.
10
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.慢性肾脏病患者的合生菌、益生元和益生菌。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013631. doi: 10.1002/14651858.CD013631.pub2.

本文引用的文献

1
Kidney Disease and Hematopoietic Stem Cell Transplantation.肾脏疾病与造血干细胞移植
Kidney360. 2025 Feb 1;6(2):317-330. doi: 10.34067/KID.0000000692. Epub 2025 Jan 9.
2
Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植后的肾移植
Kidney Int Rep. 2024 Jan 30;9(4):1127-1131. doi: 10.1016/j.ekir.2024.01.048. eCollection 2024 Apr.
3
Impact of waitlist time on post-HSCT survival: a cohort study at a hospital in southern Brazil.等待时间对异基因造血干细胞移植后生存率的影响:巴西南部一家医院的队列研究
Hematol Transfus Cell Ther. 2024 Jul-Sep;46(3):242-249. doi: 10.1016/j.htct.2023.03.021. Epub 2023 May 22.
4
An approach to treating older adults with chronic kidney disease.一种治疗老年慢性肾脏病患者的方法。
CMAJ. 2023 May 1;195(17):E612-E618. doi: 10.1503/cmaj.221427.
5
Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant.慢性肾脏病、同种异体造血干细胞移植受者的生存率及无移植物抗宿主病/无复发生存率
Clin Kidney J. 2022 Apr 7;15(8):1583-1592. doi: 10.1093/ckj/sfac091. eCollection 2022 Aug.
6
Kidney Disease Following Hematopoietic Stem Cell Transplantation.造血干细胞移植后的肾脏疾病。
Adv Chronic Kidney Dis. 2022 Mar;29(2):103-115.e1. doi: 10.1053/j.ackd.2021.11.003.
7
Sex-Based Differences in Risk Factors and Complications of Chronic Kidney Disease.性别差异与慢性肾脏病的危险因素和并发症。
Semin Nephrol. 2022 Mar;42(2):153-169. doi: 10.1016/j.semnephrol.2022.04.006.
8
Predictors of kidney complications and analysis of hypertension in children with allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植儿童肾并发症的预测因素及高血压分析。
Pediatr Nephrol. 2023 Feb;38(2):461-469. doi: 10.1007/s00467-022-05599-x. Epub 2022 May 20.
9
Epidemiology of chronic kidney disease: an update 2022.慢性肾脏病流行病学:2022年最新情况
Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18.
10
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.Narsoplimab,甘露聚糖结合凝集素相关丝氨酸蛋白酶-2 抑制剂,用于治疗成人造血干细胞移植相关性血栓性微血管病。
J Clin Oncol. 2022 Aug 1;40(22):2447-2457. doi: 10.1200/JCO.21.02389. Epub 2022 Apr 19.